anti cd8a antibody  (Bio X Cell)

Journal: JCI Insight

Article Title: DNA delivered by lipid nanoparticles induces CD8 + T cell–dependent antitumor responses and enhances anti–PD-L1 therapy

doi: 10.1172/jci.insight.197404

Figure Lengend Snippet: HDTVI-induced HCC-bearing mice received a single i.v. dose of 1 μg of DNA-LNP 3 weeks after HCC induction. Livers were harvested and analyzed at days 5 and 14 after treatment. ( A ) Cell-type profiling by NanoString. ( B ) qRT-PCR analysis of CD8a. ( C ) Representative images (20×) and ( D ) quantification of IHC analysis of CD8 + cells from liver sections. Min-to-max whiskers are shown in the box and whiskers plot. Data were analyzed by 1-way ANOVA with Tukey’s multiple-comparison test. * P < 0.05.

Article Snippet: In some experiments, anti-mouse CD8A antibodies (InVivoMAb, BE0061 clone 2.43, Bio X Cell) were i.p. administered on days –2, 1, 4, and 7 after DNA-LNP dosing at a dose of 200 μg/mouse in a total volume of 100 μL starting at day 1 after DNA-LNP dosing.

Techniques: Quantitative RT-PCR, Comparison

Journal: JCI Insight

Article Title: DNA delivered by lipid nanoparticles induces CD8 + T cell–dependent antitumor responses and enhances anti–PD-L1 therapy

doi: 10.1172/jci.insight.197404

Figure Lengend Snippet: ( A – D ) B16-F10 tumor-bearing mice (s.c.) were intratumorally dosed with DNA-LNP at days 0 and 3. Tumors were collected at day 7 and analyzed using flow cytometry. ( A ) Numbers of indicated immune cells per milligram of tumor tissues. ( B ) CD4/CD8 ratio. ( C ) Percentage of Granzyme B + cells and ( D ) CD69 + cells from CD8 + T cells or NK cells. ( E and F ) Mice with B16-F10 lung metastasis were i.v. dosed at days 0, 3, and 6, and lung sections were analyzed at day 13 by CD8 IHC. ( E ) Representative images of lung sections and ( F ) quantification of CD8 + cells. Min-to-max whiskers are shown in the box and whiskers plot. Data shown as mean ± SD. Data were analyzed by 1-way ANOVA with Tukey’s multiple-comparison test. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001.

Article Snippet: In some experiments, anti-mouse CD8A antibodies (InVivoMAb, BE0061 clone 2.43, Bio X Cell) were i.p. administered on days –2, 1, 4, and 7 after DNA-LNP dosing at a dose of 200 μg/mouse in a total volume of 100 μL starting at day 1 after DNA-LNP dosing.

Techniques: Flow Cytometry, Comparison

Journal: JCI Insight

Article Title: DNA delivered by lipid nanoparticles induces CD8 + T cell–dependent antitumor responses and enhances anti–PD-L1 therapy

doi: 10.1172/jci.insight.197404

Figure Lengend Snippet: HDTVI-induced HCC-bearing mice ( n = 11) received a single i.v. dose of 1 μg of DNA-LNP 3 weeks after HCC induction. Mice received 200 μg of anti-CD8 or anti-NK1.1 (i.p.) at days –2, 1, 4, and 7 to deplete CD8 + T cells or NK cells, respectively. ( A ) Tumor growth indicated by serum GLuc activity. ( B ) Survival curves. Survival data were analyzed by log-rank (Mantel-Cox) tests. * P < 0.05, *** P < 0.001, and ns (not significant).

Article Snippet: In some experiments, anti-mouse CD8A antibodies (InVivoMAb, BE0061 clone 2.43, Bio X Cell) were i.p. administered on days –2, 1, 4, and 7 after DNA-LNP dosing at a dose of 200 μg/mouse in a total volume of 100 μL starting at day 1 after DNA-LNP dosing.

Techniques: Activity Assay

Journal: JCI Insight

Article Title: DNA delivered by lipid nanoparticles induces CD8 + T cell–dependent antitumor responses and enhances anti–PD-L1 therapy

doi: 10.1172/jci.insight.197404

Figure Lengend Snippet: Mouse tumor models received 200 μg of anti-CD8 or anti-NK1.1 (i.p.) at day –2, 1, 4, and 7 to deplete CD8 + T cells or NK cells, respectively. ( A ) Survival curves of C1498 AML tumor-bearing mice ( n = 8) after i.v. administration of 5 μg of DNA-LNP at days 0, 3, and 6. ( B ) Tumor growth curves and ( C ) survival curves of B16-F10 tumor-bearing mice ( n = 7) after intratumoral administration of 10 μg of DNA-LNP at days 0, 3, and 6. Survival data were analyzed by log-rank (Mantel-Cox) tests. * P < 0.05, ** P < 0.01, *** P < 0.001, and ns (not significant).

Article Snippet: In some experiments, anti-mouse CD8A antibodies (InVivoMAb, BE0061 clone 2.43, Bio X Cell) were i.p. administered on days –2, 1, 4, and 7 after DNA-LNP dosing at a dose of 200 μg/mouse in a total volume of 100 μL starting at day 1 after DNA-LNP dosing.

Techniques:

Journal: Science Advances

Article Title: PROTAC-based synthetic lethality strategy endogenously activates systemic STING to boost antitumor immunity

doi: 10.1126/sciadv.ado7448

Figure Lengend Snippet: ( A ) Schematic diagram of immune system activation. ( B ) Representative flow cytometric analysis and relative quantifications of mature DCs in tumor-draining lymph node cells after indicated treatment. ( C ) Analysis of B16F10 tumors after 21 days of treatment for effector cytokine production by intratumoral CD8 + T cells. Representative flow cytometric analysis images ( D ) and relative quantifications ( E ) of IFN-γ + CD8 + and GzmB + CD8 + T cells in the tumor. TILs, tumor-infiltrating lymphocytes. ( F and G ) Analysis of spleen in B16F10 tumor–bearing mice after 21 days of treatment for effector cytokine production by CD8 + T cells. ( H and I ) Analysis of spleen in B16F10 tumor–bearing mice after 21 days of treatment for effector cytokine production by NK + cells. ( J ) Analysis of B16F10 tumors after 21 days of treatment for effector cytokine production by intratumoral NK + cells. Representative flow cytometric analysis images ( K ) and relative quantifications ( L ) of IFN-γ + NK + and GzmB + NK + cells in the tumor. ( M to O ) Representative flow cytometric analysis and quantification of CD4 + CD25 + Foxp3 + cells in the tumor tissues and spleen. Results are presented as the means ± SD.

Article Snippet: For the depletion of CD8 + T cells and NK1.1 cells in vivo, anti-CD8a antibodies (aCD8, 300 μg per mouse, BioXcell, catalog number BE0061, clone number 2.43) and anti-NK1.1 antibodies (aNK1.1, 300 μg per mouse, BioXcell, catalog number BE0036, clone number PK136) were intraperitoneally injected.

Techniques: Activation Assay

Journal: Science Advances

Article Title: PROTAC-based synthetic lethality strategy endogenously activates systemic STING to boost antitumor immunity

doi: 10.1126/sciadv.ado7448

Figure Lengend Snippet: ( A ) Schematic illustration of the timeline for B16F10-Luc tumor inoculation and treatments in a C57BL/6 mouse model. ip, intraperitoneally. ( B ) In vivo bioluminescence imaging of B16F10-Luc tumor growth after administration with different formulations. n = 3 biologically independent samples. d, days. ( C ) Data analysis of the bioluminescence signals of the mice. Representative flow cytometry analysis plots of CD8 + T cells ( D ) and NK1.1 cells ( E ) in the spleens of mice after receiving LNP@PRO P+B and aCD8 + aNK1.1 + LNP@PRO P+B treatments. ( F ) Schematic diagram of the treatment process for the lung metastasis model. ( G ) Representative images of the excised lungs from each treatment group following the completion of the treatment. Yellow dashed lines indicate lung metastases. n = 5 biologically independent samples. ( H ) H&E-stained sections of the lungs of each treatment group after the end of treatment. ( I ) Statistics of the number of lung metastatic nodules in each treatment group after the end of treatment. ( J ) Weight of lung metastatic nodules in each treatment group after the end of treatment. ( K ) Representative flow cytometry analysis plots of CD8 + T cells and CD4 + T cells in the spleens of mice after receiving LNP@PRO P , LNP@PRO B , and LNP@PRO P+B treatments. ( L ) Quantitative analysis of the T EM cells and T CM cells in CD8 + T cells after the above treatments ( n = 5). ( M ) Representative flow cytometry analysis plots of T EM cells and T CM cells in CD8 + T cells after the above treatments. ( N ) Quantitative analysis of the T EM cells and T CM cells in CD4 + T cells after the above treatments ( n = 5). ( O ) Representative flow cytometry analysis plots of T EM and T CM cells in CD4 + T cells after the above treatments. Results are presented as the means ± SD.

Article Snippet: For the depletion of CD8 + T cells and NK1.1 cells in vivo, anti-CD8a antibodies (aCD8, 300 μg per mouse, BioXcell, catalog number BE0061, clone number 2.43) and anti-NK1.1 antibodies (aNK1.1, 300 μg per mouse, BioXcell, catalog number BE0036, clone number PK136) were intraperitoneally injected.

Techniques: In Vivo, Imaging, Flow Cytometry, Staining